Verition Fund Management
DSGN icon

Verition Fund Management’s Design Therapeutics DSGN Stock Holding History

Verition Fund Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-27,045
Closed -$90.6K – 3262
2024
Q2 		$90.6K Buy
+27,045
New +$105K ﹤0.01% 2738
2023
Q3 		– Sell
-11,786
Closed -$74.3K – 2423
2023
Q2 		$74.3K Sell
11,786
-32,394
-73% -$198K ﹤0.01% 2008
2023
Q1 		$255K Buy
+44,180
New +$330K ﹤0.01% 1622

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Verition Fund Management's DSGN Position: Q3 2024 in Review

Verition Fund Management sold out of Design Therapeutics (DSGN) in Q3 2024, closing a stake of 27,045 shares — an estimated $90.6K sold.

Verition Fund Management first reported a position in DSGN in Q1 2023 and held it in 3 quarters. The position peaked at $255K in Q1 2023. 100 funds tracked by Wall St. Rank hold DSGN as of Q3 2024.

  • Verition Fund Management reported no remaining Design Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Verition Fund Management sold 27,045 Design Therapeutics shares in Q3 2024, an estimated $90.6K.
  • Verition Fund Management first reported a position in Design Therapeutics in Q1 2023 and held it in 3 quarters.
  • Verition Fund Management's Design Therapeutics position peaked at $255K in Q1 2023.
  • 100 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2024.

Based on Verition Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.